We are live on ! Find out more
BCTX

Briacell Therapeutics
BCTX

22 hedge funds and large institutions have $20.3M invested in Briacell Therapeutics in 2021 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 3 increasing their positions, reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,300% more capital invested

Capital invested by funds: $1.45M → $20.3M (+$18.8M)

467% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 3

175% more funds holding

Funds holding: 8 → 22 (+14)

23.91% more ownership

Funds ownership: 2.62% → 26.53% (+24%)

Holders
22
Holders Change
+14
Holders Change %
+175%
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
3
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACM
Altium Capital Management
New York
+$3.33M
2
AC
Armistice Capital
New York
+$2.37M
3
KC
Kepos Capital
New York
+$2.08M
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$1.66M
5
MI
MMCAP International
Cayman Islands
+$1.66M

Top Sellers

Rank Fund Capital Flow
1
ZCA
Zeke Capital Advisors
Pennsylvania
-$174K
2
VF
Virtu Financial
New York
-$58K
3
Osaic Holdings
Osaic Holdings
Arizona
-$24.9K

BCTX Hedge Fund Activity: Q2 2021 in Review

22 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in Briacell Therapeutics (BCTX) for Q2 2021, worth a combined $20.3M — up 1,300% from $1.45M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new BCTX positions and 3 closed out — a net gain of 14 holders — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Altium Capital Management, opening a new position worth an estimated $3.33M. The largest seller was Zeke Capital Advisors, exiting entirely with an estimated $174K sold.

  • 22 institutional investors held Briacell Therapeutics (BCTX) as of Q2 2021, up from 8 in Q1 2021.
  • Funds reported $20.3M of Briacell Therapeutics stock for Q2 2021, up 1,300% quarter-over-quarter.
  • 17 funds opened new Briacell Therapeutics positions in Q2 2021 and 3 closed out, a net change of +14 holders.
  • The largest Briacell Therapeutics buyer in Q2 2021 was Altium Capital Management, an estimated $3.33M added.
  • The largest Briacell Therapeutics seller in Q2 2021 was Zeke Capital Advisors, an estimated $174K sold.

Based on aggregated 13F filings for Q2 2021.